Vaccination against IL-31 for the treatment of atopic dermatitis in dogs

[...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of allergy and clinical immunology Ročník 142; číslo 1; s. 279 - 281.e1
Hlavní autoři: Bachmann, Martin F., Zeltins, Andris, Kalnins, Gints, Balke, Ina, Fischer, Nina, Rostaher, Ana, Tars, Kaspars, Favrot, Claude
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.07.2018
Elsevier Limited
Témata:
Antigens
Atopic dermatitis
Dermatitis
Dogs
Immunization
Quality of life
Skin diseases
Vaccination
Viruses
United States > US
Europe
ISSN:0091-6749, 1097-6825, 1097-6825
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:[...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets Janus kinase 1, a downstream molecule of a number of cytokines including those pivotal for the allergic reaction, including IL-31.3 In animals and humans, IL-4 and IL-13 are known to be critical for the inflammatory process in AD, while IL-31 is pivotal for the itching.1 Furthermore, an mAb against IL-31 has recently been approved for the treatment of AD in dogs.4 Both Apoquel as well as the mAb against IL-31 have to be given relatively frequently (twice daily for Apoquel and monthly for the antibody). [...]vaccination against IL-31, which should induce a more sustained antibody response, may be a valuable addition or alternative to existing therapies. Dogs were immunized with 100 μg CMVTT formulated in alum on day 0. Because the vaccine was well tolerated and caused no itching, the dose was increased to 300 μg on weeks 3 and 6 (see Fig 1, B, for study outline).
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
ISSN:0091-6749
1097-6825
1097-6825
DOI:10.1016/j.jaci.2017.12.994